For patients with NSCLC BMs, the efficacy of other ICIs remain unknown, whose targets are T‐cell immunoglobulin‐3 (Tim‐3), OX40 (CD134), 4‐1BB (CD137), pyridine 2, 3‐dioxygenase‐1, killer cell immunoglobulin‐like receptors. Here, TNFRSF4 is linked to non-small cell lung carcinoma.